References
- World Health Assembly. Eradication of poliomyelitis by the year 2000: resolution of the World Health Assembly. Geneva, Switzerland: World Health Organization (WHA resolution. 41.28); 1988.
- Henderson RH, Keja J, Hayden G, et al. Immunising the children of the world: progress and prospects. Bull WHO. 1988;66:535–543.
- Ward NA, Milstien JB, Hull HF, et al. The WHO-EPI initiative for the global eradication of poliomyelitis. Biologicals. 1993;21(4):327–333. PMID: 8024747. doi:10.1006/biol.1993.1092.
- Wood D, Sutter RW, Dowdle W. Stopping vaccination following poliomyelitis erdication: issues and challenges. Bull WHO. 2000;78:347–357.
- Report of WHO Director General on Achievements of EPI, to the Execurive Board 1991 EB89_17_eng.pdf. World Health Assembly, 44.; 1991. Report of the Director-General on the work of WHO in 1991. World Health Organization. Available from: https://iris.who.int/handle/10665/173728.
- Wright PF, Kim-Farley RJ, deQuadros CA, et al. Strategies for the global eradication of poliomyelitis by the year 2000. NEJM. 1991;325:1774–1779.
- Hull HF, Ward NA, Hull BP, et al. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet. 1994;343(8909):1331–1337. doi:10.1016/s0140-6736(94)92472-4.
- Soudarssanane MB, Rotti SB, Srinivasa DK, et al. Paralytic poliomyelitis in children under 6 years in Pondicherry: a community survey. J Epidemiol Community Health. 1993;47(3):210–214. doi:10.1136/jech.47.3.210.
- LaForce FM, Lichnevski MS, Keja J, et al. Clinical survey techniques to estimate prevalence and annual incidence of poliomyelitis in developing countries. Bull World Health Organ. 1980;58(4):609–620.
- Ghendon Y, Robertson SE. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull WHO of Polioviruses. 1994;72:973–983.
- Global Polio Eradication Initiative. Global eradication of wild poliovirus type 2 declared. Available from: https://polioeradication.org/news-post/global-eradication-of-wild-poliovirus-type-2-declared/.
- Hull HF. Progress towards global polio eradication. Dev Biol. 2001;105:3–7.
- Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59(1):587–635. PMID: 16153180. doi:10.1146/annurev.micro.58.030603.123625.
- World Health Organization. 08. Polio Weekly Update. Switzerland WHO; Geneva; 2024.
- Bandyopadhyay AS, Zipursky S. A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story. Lancet Infect Dis. 2023;23(2):e67–e71. doi:10.1016/S1473-3099(22)00582-5.
- John TJ, Dharmapalan D, Steinglass R, et al. nOPV is still not the right tool for eradication. Indian Pediatr. 2024;61(4):387–387. doi:10.1007/s13312-024-3166-4.
- GPEI. ; 2023GPEI Statement on cVDPV2 detections in Burundi and Democratic Republic of the Congo. 16 March. https://polioeradication.org/news-post/gpei-statement-on-cvdpv2-detections-in-burundi-and-democratic-republic-of-the-congo/.
- Lapinleimu K. Elimination of poliomyelitis in Finland. Rev Infect Dis. 1984;6(Supplement_2):S457–S460. doi:10.1093/clinids/6.supplement_2.s457.
- Bottiger M. The elimination of polio in the Scandinavian countries. Pub Health Rev. 1993;21:27–33.
- GPEI. Supplementary Immunization. Available from: https://polioeradication.org/who-we-are/polio-endgame-strategy-2019-2023/supplementary-immunization/.
- Horstmann DM. Poliomyelitis: severity and type of disease in different age groups. Ann N Y Acad Sci. 1955;61(4):956–967. doi:10.1111/j.1749-6632.1955.tb42554.x.
- Sabin AB. Pathogenesis of poliomyelitis; reappraisal in the light of new data. Science. 1956;123(3209):1151–1157. doi:10.1126/science.123.3209.1151.
- Paul JR, Horstmann DM, Riordan JT, et al. An oral poliovirus vaccine trial in Costa Rica. Bull World Health Organ. 1962;26(3):311–329.
- Melnick JL, Plotkin SA, Mortimer EA. Live attenuated poliovaccines. Chapter 7 in Vaccines. Philadelphia: WB Saunders Co; 1988. p. 115–137.
- Grassly NC, Jafari H, Bahl S, et al. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. J Infect Dis. 2012;205(10):1554–1561. Epub 2012 Mar 23. PMID: 22448007. doi:10.1093/infdis/jis241.
- Mach O, Verma H, Khandait DW, et al. Prevalence of asymptomatic poliovirus infection in older children and adults in northern India: analysis of contact and enhanced community surveillance, 2009. J Infect Dis. 2014;210(Suppl 1):S252–S8. doi:10.1093/infdis/jit234.
- John TJ, Dharmapalan D, Steinglass R, et al. The role of adults in poliovirus transmission to infants and children. Glob Health Sci Pract. 2024;12(2):e2300363. doi:10.9745/GHSP-D-23-00363.
- WHO. Statement following the Thirty-seventh Meeting of the IHR Emergency Committee for Polio22 December 2023 Statement. Available from: https://www.who.int/news/item/22-12-2023-statement-following-the-thirty-seventh-meeting-of-the-ihr-emergency-committee-for-polio.
- John TJ, Dharmapalan D. Lessons from Vaccine-related poliovirus in Israel, UK and USA. Vaccines. 2022;10(11):1969. doi:10.3390/vaccines10111969.
- World Health Organisation. Poliomyelitis (polio). Available from: https://www.who.int/health-topics/poliomyelitis#tab=tab_2.
- John TJ, Samuel BU, Christhuraj S. Method to increase the sensitivity of poliovirus isolation. Lancet. 1992;340(8825):975. doi:10.1016/0140-6736(92)92863-b.
- Gelfand HM, LeBlanc DR, Fox JP, et al. Studies on the development of natural immunity to poliomyelitis in Lousiana. II. Description and analysis of episodes of infection observed in study households. Amer J Hyg. 1957;65:367–385.
- Ogra PL, Fishaut M, Gallagher MR. Viral vaccination via the mucosal routes. Rev Infect Dis. 1980;2(3):352–369. doi:10.1093/clinids/2.3.352.
- Roberston S. Module 6: Poliomyelitis. Global programme for vaccines and immunization. immunological basis for immunisation series. Geneva: World Health Organisation; 1993.
- Centers for Disease Control and Prevention (CDC). Update on vaccine-derived polioviruses. MMWR Morb Mortal Wkly Rep. 2006;55(40):1093–1097.
- John TJ. Problems with oral polio vaccine in India. Indian Pediatr. 1972;9(5):252–256.
- Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13(5):926–939. PMID: 1660184. doi:10.1093/clinids/13.5.926.
- Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol. 1999;150(10):1001–1021. PMID: 10568615. doi:10.1093/oxfordjournals.aje.a009924.
- O’Leary A. Overcoming challenges en route to polio eradication. Lancet. 2022;400(10359):1191. doi:10.1016/S0140-6736(22)01880-3.
- Sabin AB. Transmission of poliomyelitis virus; analysis of differing interpretations and concepts, practical implications. J Pediatr. 1951;39(5):519–531. doi:10.1016/s0022-3476(51)80173-2.
- Neutra MR, Frey A, Kraehenbuhl JP. Epithelial M cells: gateways for mucosal infection and immunisation. Cell. 1996;86(3):345–348. doi:10.1016/s0092-8674(00)80106-3.
- Wahid R, Cannon MJ, Chow M. Dendritic cells and macrophages are productively infected by poliovirus. J Virol. 2005;79(1):401–409. doi:10.1128/JVI.79.1.401–409.
- Pfeiffer JK. Innate host barriers to viral trafficking and population diversity: lessons learned from poliovirus. Adv Virus Res. 2010;77:85–118. doi:10.1016/B978-0-12-385034-8.00004-1.
- Selvakumar R, John TJ. Intestinal immunity to poliovirus develops only after repeated infections in monkeys. J Med Virol. 1989;27(2):112–116. doi:10.1002/jmv.1890270208.
- John TJ, Samuel R. Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol. 2000;16(7):601–606. PMID: 11078115 doi:10.1023/a:1007626510002.
- Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83–100. doi:10.1038/s41577-020-00479-7).
- Stickle G. Observed and expected poliomyelitis in the United States, 1958–1961. Am J Public Health Nations Health. 1964;54(8):1222–1229. doi:10.2105/ajph.54.8.1222.
- John TJ. Immunisation against polioviruses in developing countries. Rev Med Virol. 1993;3(3):149–160. doi:10.1002/rmv.1980030305.
- Simoes EA, Padmini B, Steinhoff MC, et al. Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child. 1985;139(10):977–980. doi:10.1001/archpedi.1985.02140120023021.
- Simoes EA, John TJ. The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency. J Biol Stand. 1986;14(2):127–131. doi:10.1016/0092-1157(86)90031-4.
- Anderson RM. Directly transmitted viral and bacterial infections of man. In: anderson RM Population dynamics of infectious diseases. London: Chapman and Hall; 1982. p. 1–137.
- Nathanson N. Eradication of poliomyelitis in the United States. Rev Infect Dis. 1982;4(5):940–950. doi:10.1093/clinids/4.5.940.
- WHO. Circulating vaccine-derived poliovirus type 1 – Papua New Guinea; [cited 2024 Feb 10]. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/20-February-2019-polio-png-en.
- GPEI. 2024. Yemen; [cited 2024 Mar 10]. Available from: https://polioeradication.org/where-we-work/polio-outbreak-countries/yemen/.
- John TJ, Dharmapalan D, Hirschhorn N, et al. How to avoid causing polio in the name of its eradication. Lancet. 2023;402(10397):179–180. doi:10.1016/S0140-6736(23)01069-3.
- John TJ, Hirschhorn N, Dharmapalan D. Choosing the right path toward polio eradication. N Engl J Med. 2023;388(19):1824. doi:10.1056/NEJMc2303169.
- Kasstan B, Mounier-Jack S, Chantler T, et al. Poliovirus outbreak in New York State, August 2022: qualitative assessment of immediate public health responses and priorities for improving vaccine coverage. Epidemiol Infect. 2023;151:e120. PMID: 37435800; PMCID: PMC10468811. doi:10.1017/S0950268823001127.
- Klapsa D, Wilton T, Zealand A, et al. Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Lancet. 2022;400(10362):1531–1538. doi:10.1016/S0140-6736(22)01804-9.